Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
The speed at which targeted therapies are being developed and incorporated into the treatment of advanced renal cell carcinoma (RCC) is surprising. After decades in which the only systemic treatment options available for advanced disease were interleukin-2 and interferon-alpha, in the last decade, six new targeted therapies have emerged showing meaningful clinical benefits to patients with advanced RCC through phase III trials. Recently, the Spanish Oncology Genitourinary Group issued its first public statement of recommendations for the optimal management of advanced RCC. However, most pivotal phase III trials on which these recommendations were based have been updated and/or fully reported. Moreover, a new multikinase inhibitor, pazopanib, has emerged with good quality clinical data. In this report, we review in depth the latest phase III data of targeted therapies for advanced RCC and update our recommendations. Furthermore, we hypothesize about the best environment for patients with advanced RCC to receive cancer therapy.
Calvo
Emiliano
E
Hospital de Madrid-CIOCC, Madrid, Spain.
Maroto
Pablo
P
del Muro
Xavier García
XG
Climent
Miguel Angel
MA
González-Larriba
José Luis
JL
Esteban
Emilio
E
López
Rafael
R
Paz-Ares
Luis
L
Bellmunt
Joaquim
J
Castellano
Daniel
D
D002292:Carcinoma, Renal Cell / Q000208:ethnology / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000208:ethnology / Q000628:therapy*; D008495:Medical Oncology; D013030:Spain